Diamyd Medical (DMYD) Investing in Life Science 2025 summary

Mission and disease overview

• Founded with a mission to cure Type 1 diabetes, inspired by a personal connection to the disease.

• Type 1 diabetes remains a significant unmet medical need, with insulin as the mainstay for over a century but not a cure.

• Over 500,000 new diagnoses annually, with societal costs nearing $100 billion per year due to complications.

• Patients face lifelong insulin dependence and a much higher risk of complications, including cardiovascular disease and reduced lifespan.

Therapy development and clinical progress

• Developing a disease-modifying therapy (Diamyd) aimed at halting the autoimmune attack on insulin-producing cells.

• Therapy is antigen-specific, non-immunosuppressive, and has shown a favorable safety profile in over 1,000 treated patients.

• Precision medicine approach: efficacy depends on a specific genetic profile present in about 40% of Type 1 diabetes patients.

• Fast track and orphan drug designations in the U.S. for all disease stages; only company with fast track for all stages.

Clinical trial data and milestones

• Phase II and III data show about 50% preservation of insulin-producing capacity compared to placebo at 15 months.

• Data suggest significant delay in disease progression, with up to a seven-year delay to clinical diagnosis in early stages.

• Ongoing pivotal phase III trial is the first precision medicine trial in Type 1 diabetes, with patient selection based on genetics.

• Only ongoing phase III trial globally for a disease-modifying therapy in this indication, with a single pivotal trial sufficient for approval.

• Early phase III readout expected March–April next year, potentially supporting accelerated approval in the U.S.